Agios Pharmaceuticals

Agios Pharmaceuticals is a biopharmaceutical company passionately committed to applying its scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism, which are a subset of orphan genetic metabolic diseases.

Agios is a first mover in using cellular metabolism, an unexploited area of biological research with disruptive potential, as a platform for developing potentially transformative medicines. The Company intends to apply its deep understanding of metabolism, coupled with its ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and rare genetic disorders of metabolism are treated.

Agios also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The Company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases.

Company Growth (employees)
Cambridge, US
Size (employees)
287 (est)
Agios Pharmaceuticals was founded in 2008 and is headquartered in Cambridge, US

Agios Pharmaceuticals Office Locations

Agios Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
88 Sidney St

Agios Pharmaceuticals Financials and Metrics

Agios Pharmaceuticals Financials

Agios Pharmaceuticals's revenue was reported to be $10.5 m in Q1, 2017

Revenue (Q1, 2017)

10.5 m

Net income (Q1, 2017)

(66.2 m)

EBIT (Q1, 2017)

(67 m)

Market capitalization (16-Oct-2017)

3.3 b

Cash (31-Mar-2017)

200.3 m
Agios Pharmaceuticals's current market capitalization is $3.3 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


25.5 m65.4 m59.1 m69.9 m

Revenue growth, %



(38.9 m)(54.1 m)(118.7 m)(201 m)

EBIT margin, %

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


8.4 m34.2 m13.2 m5.5 m31.3 m7 m9 m10.5 m

R&D expense

22.6 m25.5 m32.4 m36.4 m36 m44 m50.8 m60.6 m62.7 m

General and administrative expense

4.2 m5.2 m7 m8.9 m9.9 m10.8 m12.6 m11.9 m14.8 m

Operating expense total

26.7 m30.7 m39.4 m45.4 m46 m54.9 m63.4 m72.5 m77.6 m
USDFY, 2013FY, 2014FY, 2015FY, 2016


71.6 m14 m71.8 m160.8 m

Accounts Receivable

2.3 m600 k


2.5 m4.8 m8.7 m10.3 m

Current Assets

169.7 m359.5 m337.3 m559.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


108.2 m70 m35.3 m72.5 m80 m39 m234 m285.5 m200.3 m

Current Assets

245.2 m247.6 m364.1 m390.2 m371.7 m329.5 m484.2 m600.9 m506.9 m


3.2 m3.7 m14.3 m19.3 m21.1 m23 m25.1 m26.3 m24.1 m

Total Assets

272 m269.6 m474.3 m474.4 m449.1 m396.1 m557.6 m672 m557.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(39.4 m)(53.5 m)(117.7 m)(198.5 m)

Depreciation and Amortization

1.4 m1.4 m3.3 m5.7 m

Accounts Receivable

(2.3 m)(1 m)

Accounts Payable

30 k7.6 m4.2 m3.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(18.3 m)3.7 m(5 m)(31.9 m)(40.3 m)(23.2 m)(56 m)(62.8 m)(66.2 m)

Accounts Payable

5.4 m6.2 m12.6 m8.9 m9 m13.7 m18.4 m15.4 m16.2 m
USDY, 2017


36.6 k

Financial Leverage

1.8 x
Show all financial metrics

Agios Pharmaceuticals Market Value History

Traffic Overview of Agios Pharmaceuticals

Agios Pharmaceuticals Online and Social Media Presence

Agios Pharmaceuticals Company Life and Culture

You may also be interested in